Luana Morelli

Dr. Luana Morelli

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MGMaria Pia Giannoccaro
Maria Pia Giannoccaro
FVFederico Verde
Federico Verde
LMLuana Morelli
Luana Morelli
GRGiovanni Rizzo
Giovanni Rizzo
FRFortuna Ricciardiello
Fortuna Ricciardiello
RLRocco Liguori
Rocco Liguori
Autoimmune encephalitis and neurodegenerative disorders share several clinical features, including behavioural and psychiatric manifestations, cognitive impairment, sleep and movement disorders. Therefore, it is not surprising that autoimmune encephalitis is one of the main differential diagnoses of rapidly progressive dementia. However, more chronic presentations of autoimmune disorders have been reported and can lead to the misdiagnosis of a neurodegenerative disease. On the other hand, antibodies against neuronal proteins, such as those directed against NMDAR, can occur during established neurogenerative disorders, and their role in this context is still unclear. They might be simple bystanders or modify the disease course and phenotype. Indeed, autoimmune encephalitis can leave long-term cognitive sequelae and specific antibodies to neuronal surface antigens are associated with clinical and pathological neurodegenerative features. Here we review the link between these antibodies and neurodegeneration. In particular we discuss: (a) the possibility that autoimmune encephalitis presents as a neurodegenerative disease, identifying the red flags that can help in the differential diagnosis between antibody-mediated and neurodegenerative disorders; (b) the occurrence of antibodies against neuronal surface antigens in patients with neurodegenerative disorders and their possible role in the disease course; and (c) the long-term cognitive and neuroradiological changes associated with autoimmune encephalitis, as well as the biomarkers that can help to predict the cognitive outcome. Finally, we review the clinical and pathological features of IgLON5 antibodies-related encephalitis, a unique model of the relationship between antibodies and neurodegeneration.

1 May 2026 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
IGIlaria Gligora
Ilaria Gligora
PBPietro Businaro
Pietro Businaro
LSLucrezia Serra
Lucrezia Serra
SPSilvia De Pasqua
Silvia De Pasqua
FRFortuna Ricciardiello
Fortuna Ricciardiello
MGMaria Pia Giannoccaro
Maria Pia Giannoccaro
Myasthenia gravis (MG) is an autoimmune disorder primarily caused by antibodies targeting neuromuscular junction proteins, particularly the acetylcholine receptor and the muscle-specific tyrosine kinase. However, 10%-20% of patients with MG are double-seronegative (dsMG). Antibodies against low-density lipoprotein receptor-related protein 4 (LRP4-IgG) have been found in a variable proportion of dsMG cases, but their frequency and clinical relevance remain unclear because of differences in assay methodologies and study populations. In this study, we assessed the frequency of LRP4-IgG in patients with suspected MG using different cell-based assay (CBA) protocols. In this multicenter observational study, we enrolled consecutive patients presenting with symptoms suggestive of MG. LRP4-IgG was tested by 2 centers using 3 different CBAs: live (l-CBA), methanol-fixed (mf-CBA), and paraformaldehyde-fixed (pf-CBA). Patients were classified as having MG or other disorders (ODs). Positive samples were cross-tested between centers. Among 684 patients (302 with MG, 382 with ODs), LRP4-IgG was detected by mf-CBA in 2% (6/302) of MG cases and in 0.52% (2/382) of OD cases. Among patients with MG, 3.9% (4/102) of dsMG and 1% (2/200) of seropositive patients tested positive. Only 50% of mf-CBA-positive cases were confirmed by pf-CBA, and none were detected by l-CBA. Cross-center testing showed partial reproducibility. LRP4-IgG detection in suspected MG is rare and inconsistent across assays, suggesting that routine testing is not currently warranted and that these antibodies are at present of limited diagnostic value. These findings highlight the need for standardized, validated LRP4-IgG assays. Future studies should focus on direct comparison and harmonization of testing protocols to clarify the clinical utility of LRP4-IgG testing.

1 December 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
MHMark Hellaby
Mark Hellaby
JWJoseph Walsh
Joseph Walsh
RARyan Ahmed
Ryan Ahmed
NCNasr Chalghaf
Nasr Chalghaf
AJAmanda Joseph
Amanda Joseph
LCLarry Chu
Larry Chu
Background: The design of personal protective equipment (PPE) may affect well-being and clinical work. PPE as an integrated item may improve usability and increase adherence by healthcare professionals. Human factors design and safety may reduce occupational-acquired diseases. As an integrated PPE, a lightweight protective air-purifying respirator (L-PAPR) could be used during health procedures where healthcare professionals are exposed to airborne pathogens. The human factors affecting the implementation of alternative PPE such as L-PAPR have not been thoroughly studied. The population of interest is health care professionals, the intervention is the performance by PPE during tasks across the three PPE types 1.) N95 respirators and face shields, 2.)traditional powered air-purifying respirator(PAPR), and 3.) L-PAPR. The outcomes are user error, communications, safety, and end-user preferences. Objective: This study will assess whether the L-PAPR improves health care professionals’ comfort in terms of perceived workload and physical and psychological burden during direct patient care when compared with the traditional PAPR or N95 and face shield. This study also aims to evaluate human factors during the comparison of the use of L-PAPR with a combination of N95 respirators plus face shields or the traditional PAPRs. Methods: This is an interventional randomized crossover quality improvement feasibility study consisting of a 3-site simulation phase with 10 participants per site and subsequent field testing in 2 sites with 30 participants at each site. The 3 types of respiratory PPE will be compared across medical tasks and while donning and doffing. We will evaluate the user’s perceived workload, usability, usage errors, and heart rate. We will conduct semistructured interviews to identify barriers and enablers to implementation across each PPE type over a single continuous wear episode and observe interpersonal communications across conditions and PPE types. Results: We expect the research may highlight communication challenges and differences in usability and convenience across PPE types along with error frequency during PPE use across PPE types, tasks, and time. Conclusions: The design of PPE may affect overall well-being and hinder or facilitate clinical work. Combining 2 pieces of PPE into a single integrated item may improve usability and reduce occupational-acquired diseases. The human factors affecting the implementation of an alternative PPE such as L-PAPR or PAPR have not been thoroughly studied. International Registered Report Identifier (IRRID): PRR1-10.2196/36549

8 September 2026 in Neurology
Verified
Journal Article
Closed access
PDF file
MGMaria Pia Giannoccaro
Maria Pia Giannoccaro
LSLucrezia Serra
Lucrezia Serra
AGAna Gabriela Grondona
Ana Gabriela Grondona
CBCorrado Ballestracci
Corrado Ballestracci
FRFortuna Ricciardiello
Fortuna Ricciardiello
RLRocco Liguori
Rocco Liguori
Background and ObjectivesAntibody testing has a pivotal role in the diagnosis of myasthenia gravis (MG). However, there are limited data on the accuracy of the different methods available for acety...

1 January 2026 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
AFAnna Fetta
Anna Fetta
FCFrancesca Conti
Francesca Conti
ALAgnese Lopalco
Agnese Lopalco
CCChiara Corsini
Chiara Corsini
MMMattia Moratti
Mattia Moratti
MGMaria Pia Giannoccaro
Maria Pia Giannoccaro
This report details a pediatric case of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) characterized by isolated MOG-IgG3 positivity and IgG1 deficiency, highlighting a unique serologic profile and exploring its immunologic significance. In addition, a review of MOGAD cases with isolated MOG-IgG3 antibodies is included. A 12-year-old boy presenting with a progressive neurologic syndrome underwent clinical, radiologic, and laboratory evaluation. MRI showed extensive brain and spinal lesions. MOG-IgG3 antibodies were identified in serum and CSF by live cell-based assay, while other MOG-IgG subclasses were not detected. Serum IgG1 was low at baseline and throughout follow-up. First-line immunotherapy treatment led to significant improvement, with no relapses at 2-year follow-up. This case highlights the potential role of subclinical IgG1 deficiency in shaping the predominance or selective detection of MOG-IgG3 in MOGAD. While most MOG antibodies are predominantly of the IgG1 isotype, our review identified a few cases with isolated MOG-IgG3 antibodies. A possible contribution to pathogenesis cannot be excluded, and the patient's inability to produce a balanced IgG subclass profile could have favored a sustained IgG3 response. Larger studies are needed to clarify the clinical significance of MOG-IgG3 in MOGAD.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
Cristiana BoiCristiana Boi
Cristiana Boi
FBFrancesca Borsetti
Francesca Borsetti
TBTommaso Maria Brugo
Tommaso Maria Brugo
Martina CappellettiMartina Cappelletti
Martina Cappelletti
MAMaria G. De Angelis
Maria G. De Angelis
FVFrancesco Saverio Violante
Francesco Saverio Violante
The outbreak of SARS-CoV-2 pandemic highlighted the worldwide lack of surgical masks and personal protective equipment, which represent the main defense available against respiratory diseases as COVID-19. At the time, masks shortage was dramatic in Italy, the first European country seriously hit by the pandemic: aiming to address the emergency and to support the Italian industrial reconversion to the production of surgical masks, a multidisciplinary team of the University of Bologna organized a laboratory to test surgical masks according to European regulations. The group, driven by the expertise of chemical engineers, microbiologists, and occupational physicians, set-up the test lines to perform all the functional tests required. In Europe, surgical masks must be labeled with the CE mark and must meet the requirements defined in EN 14683:2019 and in EN ISO 10993-1. Four test lines were assembled to perform the required tests, namely breathability, bacterial filtration efficiency (BFE), microbial cleanliness (bioburden), and splash test (for IIR type masks). According to the standard, the experimental workflow included first a breathability test that was used to exclude non-suitable materials on the basis of the air permeability. Suitable masks were then tested for BFE, which provides the indication on the filtration capabilities towards droplets with size within the range of the breathing aerosol. Eventually, the microbial cleanliness of the masks was also assayed as an additional parameter of user safety. For masks of Type IIR, the resistance to blood penetration was determined by means of the splash test using synthetic blood. The laboratory started its activity on late March 2020, and as of the end of December of the same year, more than 600 surgical mask prototypes were tested, with nearly 1200 tests performed in total. Here, a critical analysis of the results is presented, with correlations between results for breathability and BFE on surgical mask prototypes. Finally, the protocols for mask testing and validation indicated in the EN standard are discussed, revealing some critical aspects and possible room for improvement. Such analysis aims to optimize the characterization methods for what concern the reliability and the accuracy, as well as the duration, of the surgical masks’ standard tests.